As reported by the National Health Executive, the UK government has outlined new measures intended to help medicines manufactured in space move more quickly from research to patient care on Earth
The initiative aims to provide biotechnology, pharmaceutical and space technology companies with a clearer regulatory pathway, supporting the journey from experiments conducted in orbit to medicines approved for clinical use.
Announced at the Space Comm Expo in London, the measures are designed to support the emerging field of in-orbit manufacturing. Researchers believe the microgravity environment in space can be used to improve the development and performance of complex biologic medicines.
To support the sector’s growth, the package includes several measures:
• New regulatory guidance covering medicines produced in space
• Case studies to help companies navigate potential approval routes
• A regulatory sandbox allowing innovators to trial new approaches while managing risk
• Closer collaboration with UK industry and supply chain partners
Scientists say microgravity creates conditions that cannot be replicated on Earth, which can influence how complex biologic drugs form and function.
Early studies indicate that medicines manufactured in space may offer several advantages:
• Greater stability and potency of medicines
• Lower levels of impurities and manufacturing variability
• Improved treatment potential for cancer, rare diseases and chronic illnesses
• New approaches to drug delivery, including the possibility of home-based cancer therapies
Be the first to comment